Sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists, and the risk of macrovascular, and microvascular complications among patients with type 2 diabetes and non-alcoholic fatty liver disease

被引：0
|
作者：
Bea, Sungho [1 ]
Filion, Kristian B. [2 ]
Shin, Ju-Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
58
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [31] The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes
    Dey, Amit K.
    Groenendyk, Jacob
    Mehta, Nehal N.
    Gourgari, Evgenia
    CLINICAL CARDIOLOGY, 2019, 42 (03) : 406 - 412
  • [32] Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany
    Auzanneau, Marie
    Seufert, Jochen
    Zimny, Stefan
    Haak, Thomas
    Zeyfang, Andrej
    Goelz, Stefan
    Hugenberg, Inge
    Pavel, Marianne
    Rosenbauer, Joachim
    Holl, Reinhard W.
    DIABETES OBESITY & METABOLISM, 2024, 26 (09): : 4116 - 4120
  • [33] Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
    Wong, Chloe
    Lee, Ming Hui
    Yaow, Clyve Yu Leon
    Chin, Yip Han
    Goh, Xin Lei
    Ng, Cheng Han
    Lim, Amanda Yuan Ling
    Muthiah, Mark Dhinesh
    Khoo, Chin Meng
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [34] ASSOCIATION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS WITH THE RISK OF DEVELOPING DEMENTIA IN PEOPLE WITH TYPE 2 DIABETES MELLITUS
    Wang, J.
    Toulis, K.
    Gokhale, K.
    Adderley, N. J.
    Clark, D.
    Dhalla, S.
    Seck, D.
    Nirantharakumar, K.
    Eteve-Pitsaer, C.
    VALUE IN HEALTH, 2023, 26 (12) : S41 - S42
  • [35] Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation
    Ertuglu, Lale A.
    Porrini, Esteban
    Hornum, Mads
    Demiray, Atalay
    Afsar, Baris
    Ortiz, Alberto
    Covic, Adrian
    Rossing, Peter
    Kanbay, Mehmet
    TRANSPLANT INTERNATIONAL, 2021, 34 (08) : 1341 - 1359
  • [36] OUTCOMES OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES
    Mahmoud, Tarek
    Yagan, Jude
    Hasan, Amal
    Gheith, Osama
    Mustafa, Mohamed
    Rida, Suzanne
    Elserwy, Nabeel
    Shaker, Mohammad
    Khaled, Mahmoud
    Nair, Prasad
    Alotaibi, Torki
    TRANSPLANT INTERNATIONAL, 2021, 34 : 119 - 119
  • [37] Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
    Qiu, Mei
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (01) : W3 - W4
  • [38] Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
    Patorno, Elisabetta
    Htoo, Phyo T.
    Glynn, Robert J.
    Schneeweiss, Sebastian
    Wexler, Deborah J.
    Pawar, Ajinkya
    Bessette, Lily G.
    Chin, Kristyn
    Everett, Brendan M.
    Kim, Seoyoung C.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (11) : 1528 - +
  • [39] Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease
    Felix Hofer
    Niema Kazem
    Ronny Schweitzer
    Andreas Hammer
    Friedrich Jakse
    Lorenz Koller
    Christian Hengstenberg
    Patrick Sulzgruber
    Alexander Niessner
    Cardiovascular Drugs and Therapy, 2021, 35 : 1161 - 1170
  • [40] Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis
    Johnson, Conner E.
    Sussman, Whitney B.
    Weeda, Erin R.
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4544 - 4550
12345